Jpmorgan Chase & CO Brooklyn Immuno Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.23 - $0.71 $165,232 - $510,065	-718,402 Reduced 89.37%	85,440 $21,000
Q2 2022 Aug 11, 2022	SELL	$0.48 - $2.03 $8,814 - $37,278	-18,364 Reduced 2.23%	803,842 $416,000
Q1 2022 May 11, 2022	BUY	$1.76 - $4.84 $386,344 - $1.06 Million	219,514 Added 36.42%	822,206 $1.69 Million
Q4 2021 Feb 10, 2022	BUY	$4.17 - $9.79 $2.43 Million - $5.7 Million	581,879 Added 2795.75%	602,692 $2.51 Million
Q3 2021 Nov 12, 2021	BUY	$8.86 - $17.05 $184,403 - $354,861	20,813 New	20,813 $193,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.